"COVID-19 dividend" almost disappeared, and Pfizer reset the revenue guidance, causing the stock price to collapse
忧郁草民乜
发表于 2023-12-14 11:56:25
1285
0
0
[The "COVID-19 Bonus" almost disappeared, and Pfizer's reset revenue guidance caused the stock price to collapse] On Wednesday, the US Eastern Time, Pfizer announced that its revenue in 2024 might be about 5 billion dollars lower than Wall Street's expectations. This caused its stock price to plummet by over 8%, reaching a new low since 2014. The COVID-19 has brought record sales to Pfizer, and with the end of the epidemic, Pfizer's share price has also been returned to its original form.
CandyLake.com is an information publishing platform and only provides information storage space services.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
Disclaimer: The views expressed in this article are those of the author only, this article does not represent the position of CandyLake.com, and does not constitute advice, please treat with caution.
转播
You may like
- Trigger circuit breaker! Soaring by over 50%! The stock price of this company has risen by over 1700% this year
- Nvidia's stock price rose 2.5% in pre-market trading and is expected to end its four consecutive declines
- Oklo, a US nuclear energy company, has signed a large power supply order, and its stock price has skyrocketed by double digits
- Micron Technology's revenue outlook falls short of analysts' expectations, causing its stock price to plummet by approximately 18% after market hours
- Micron Technology's revenue outlook falls short of analysts' expectations, causing its stock price to plummet by approximately 18% after market hours
- Tesla's stock price plummeted! Market value evaporated by 1.38 trillion yuan in 3 days
- TSMC's stock price once hit a historical high of NT $1095
- TSMC becomes the darling of the AI era, with its stock price hitting a historic high during trading
- Eli Lilly's new Alzheimer's disease drug launched: annual drug cost exceeds $30000, Pfizer Roche is expanding its strategy
- Nvidia may launch robot 'brain' in the first half of next year, with the company's stock price increasing by over 176% since the beginning of this year
